Dyslipidemia – Unmet Need – Detailed, Expanded Analysis (US/EU)
Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD), which is primarily managed by statin therapy. With positive CV outcomes data for certain nonstatin therapies including PCSK9 inhibitors and Vascepa, the ability to reduce the risk of CV morbidity and mortality is highly desired by physicians. We discuss how current therapies are differentiated based on the performance of key drug attributes and measure the impact of these attributes on physicians’ prescribing behavior. We also assess the most important unmet needs in the treatment of dyslipidemia and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for dyslipidemia.
QUESTIONS ANSWERED
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- Which dyslipidemia therapies are perceived by U.S. and European physicians as performing best on key treatment drivers and goals?
- What are the major areas of opportunity for drug developers in dyslipidemia treatment and their likelihood of being fulfilled in the near future?
- Based on the conjoint analysis and target product profile (TPP) simulation, what trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new dyslipidemia drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in March 2021
Key companies: Amgen, Regeneron, Amarin, Esperion, Novartis, Merck
Key drugs: Repatha, Vascepa, Nexletol / Nilemdo, Nexlizet / Nustendi, ezetimibe, fibrates, omega-3 acid ethyl esters
Table of contents
- Dyslipidemia - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Executive Summary
- Unmet Need - Dyslipidemia - Executive Summary - July 2021
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Rationale for Drug Selection
- Products for Dyslipidemia and Rationale for Drug Selection
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Cardiologists' Prescribing Decisions in Dyslipidemia
- Importance of Efficacy Attributes to Prescribing Decisions in Dyslipidemia: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Dyslipidemia: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Dyslipidemia: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Dyslipidemia: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Dyslipidemia: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Dyslipidemia: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Dyslipidemia: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Dyslipidemia: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Dyslipidemia: United States
- Overall Performance of Key Therapies for Dyslipidemia: Europe
- Mean Overall Performance of Key Therapies for Dyslipidemia: United States and Europe
- Relative Performance of Key Therapies for Dyslipidemia Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Dyslipidemia Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Dyslipidemia Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Dyslipidemia Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Dyslipidemia Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Dyslipidemia Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Dyslipidemia
- Surveyed Cardiologistsu2019 Satisfaction with the Performance of Key Therapies for Dyslipidemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Cardiologistsu2019 Satisfaction with the Performance of Key Therapies for Dyslipidemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Dyslipidemia: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Dyslipidemia: Europe
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Dyslipidemia: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Dyslipidemia: Europe
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Dyslipidemia: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Dyslipidemia: Europe
- Key Findings: Unmet Need in Dyslipidemia and Related Indications
- Surveyed Cardiologists' Ascribed Level of Unmet Need in Dyslipidemia and Related Indications: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need in Dyslipidemia and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the Dyslipidemia Market and Emerging Therapy Insights
- Opportunity: LDL-Cholesterol-Lowering Drugs With New Mechanisms of Action
- Opportunity: Novel Drugs Targeting Residual Cardiovascular Risk
- Opportunity: Innovative Agents That Reduce Lipoprotein(a) Levels
- Opportunity: Different Mechanisms of Action Targeting Function and Quantity of HDL-Cholesterol
- Areas of Opportunity in the Dyslipidemia Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attribute Importance and Part-Worth Utilities
- Dyslipidemia Target Product Profile: Attribute Importance
- Effect on Major Cardiovascular Event Rate (in Addition to Standard of Care)
- Effect on LDL-Cholesterol Levels (from Baseline)
- Effect on Triglyceride Levels (from Baseline)
- Effect on HDL-Cholesterol Levels (from Baseline)
- Effect on Lipoprotein(a) Levels (from Baseline)
- Treatment Burden (Route of Administration and Frequency)
- Price per Day
- Conjoint Analysis-Based Simulation of a Market Scenario
- Dyslipidemia Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
- Dyslipidemia Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
- Dyslipidemia Market Simulation: Target Product Profiles Included in the Market Scenario
- Appendix
- Bibliography
- Executive Summary
Saptaswa Sen, Ph.D., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Disorders team at Clarivate. Prior to joining the company, he held postdoctoral research positions at the University of Kansas, where he worked on the development of novel inhibitors of the hepatitis C virus, and the Royal Institute of Technology in Stockholm, where he investigated the properties of cancer cells through modern imaging techniques. As a research fellow at the Tata Institute of Fundamental Research in Mumbai, Dr. Sen studied the biochemical functions of diverse proteins. He holds a Ph.D. degree in biochemistry-biophysics from Leiden University, where he developed innovative optical techniques for biosensing applications of enzymes and proteins.